Polaris launches Dewpoint Therapeutics with $60M to drug biomolecular condensates

January 30th, 2019 | FierceBiotech

Dewpoint Therapeutics debuted Wednesday with $60 million in series A financing and a mission to develop a drug platform that targets biomolecular condensates, an “understudied” type of organelle found inside cells. The hope is a better understanding of these structures will pave the way for new approaches to treating “the toughest diseases.”

Full article